Developer docs
API playgroundTry for free, no card

Search company profiles

eXmoor Pharma

Full company profile

uuid0000epf

Namestring
eXmoor Pharma
Legal namestring
eXmoor pharma concepts ltd
Company typeenum
Private
Founded yearint
2004
Descriptiontext

eXmoor Pharma is a UK-based integrated cell and gene therapy (CGT) contract development and manufacturing organization (CDMO) headquartered in Bristol. Founded in 2004 and operating in the CGT sector since 2007, the company delivers five interconnected service pillars: CMC consulting, process development, analytical services, GMP manufacturing, and facility design. Its purpose-built Cell & Gene Therapy Centre comprises 65,000 sq ft with four independent Grade C GMP clean rooms, a dedicated fill-finish suite, and capacity for 2x200L bioreactor scale or five autologous cell therapy stations. The facility received MHRA MIA(IMP) licensing in August 2024, enabling full GMP-grade manufacture for clinical trials.

The company serves 190+ clients globally including biotech companies (Quell Therapeutics, Tenpoint, Tavira, Imophoron), academic institutions (King's College London, UCL), nonprofits (Cancer Research UK, Anthony Nolan), and NHS partners (Royal Free London). Its differentiated integrated model embeds 20+ years of consultancy expertise across the full CMC journey, from early-phase strategy through to commercial readiness. The company employs 80+ experts, with 70% repeat business rate, and is backed by Kineticos Ventures and MVM Partners following a $35M Series A in May 2023.

Revenue is generated primarily through professional services fees for consulting, process development, and analytical work, plus managed services revenue from GMP manufacturing. The company targets enterprise clients through a direct sales team led by a Chief Commercial Officer, supplemented by industry events (BIO, ISCT, ESGCT), academic clinics with partner universities, and strategic regional partnerships including a Bangkok-based Southeast Asia expansion with Siam Bioscience announced in 2025. Geographic reach extends across the UK, US, Europe, and Southeast Asia, with planned facility expansion of 12,000 sq ft and headcount growth to 200 by 2027.

Short descriptiontext

eXmoor Pharma is an integrated UK-based cell and gene therapy CDMO offering CMC consulting, process development, analytical services, GMP manufacturing, and facility design. Founded in 2004, it serves 190+ biotech, academic, and pharma clients from its MHRA-licensed 65,000 sq ft Bristol facility with 80+ experts.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersBristol, United Kingdom
HQ citystring
Bristol
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
cell and gene therapy CDMO, GMP manufacturing services, biopharmaceutical consulting, process development services, facility design engineering
Industry4 codes
PRIMARYHLAAACAJ
Gene Therapy Vector Manufacturing & CDMO Services
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAGABAG
Drug Substance–Drug Product Integrated CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAK
Clinical Trial Material (CTM) Manufacturing & Supply CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGAHAL
GMP Scale-Up, Tech Transfer & Process Validation (PPQ)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services
NAICS code3 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
  • Pharmaceutical and Medicine Manufacturing32541
SIC code2 codes
  • Services-Commercial Physical & Biological Research8731
  • Services-Medical Laboratories8071
Product category
Cell and Gene Therapy CDMO Services
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model5 records
1Consulting Services
TypeProfessional Services
Description

CMC consulting, regulatory strategy, cost of goods analysis, investor and technical due diligence, GMP compliance consulting, and interim leadership positions. Revenue generated through project-based consulting engagements.

exmoorpharma.com
2Process Development Services
TypeProfessional Services
Description

Process development for cell therapy, viral vectors, and RNA technologies including optimization and scale-up services.

exmoorpharma.com
3Analytical Services
TypeProfessional Services
Description

Quality control and analytical testing services to ensure product safety, efficacy, and regulatory compliance.

exmoorpharma.com
4GMP Manufacturing
TypeManaged Services
Description

Clinical and commercial manufacturing services including clinical manufacturing, commercial manufacturing, cell banking, and fill finish under MHRA-licensed facility.

exmoorpharma.com
5Facility Design & Process Engineering
TypeProfessional Services
Description

Concept design and process engineering services for CGT facility planning.

exmoorpharma.com
Marketing channels8 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Operations, Infrastructure, Technology or R&D, Marketing or Sales, Supply Chain
Pricing details1 tier
1Custom project-based pricing for consulting and development services
ModelOtherBilling cadenceMulti-year contract
Notes

Pricing varies based on project scope, therapy modality, development stage, and service requirements. No public pricing tiers available.

exmoorpharma.com
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

eXmoor Pharma is an integrated cell and gene therapy Contract Development and Manufacturing Organization (CDMO) that combines 20+ years of CMC and regulatory consultancy with a purpose-built 65,000 sq ft MHRA-licensed GMP manufacturing facility in Bristol, UK. It delivers end-to-end services across consulting, process development, analytical services, GMP manufacturing (clinical and commercial), and facility design for viral vectors, autologous and allogeneic cell therapies, and RNA technologies. The integrated model enables clients to progress therapies from early-phase strategy through to commercial readiness under a single provider.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 70% repeat business rate demonstrating high client satisfaction
+4 more records
Product overview1 text field

eXmoor Pharma is an integrated cell and gene therapy CDMO offering five interconnected service pillars: Consulting Services (CMC strategy, GMP compliance, QP services, due diligence), Process Development (cell therapy, viral vector, RNA), Analytical Services, GMP Manufacturing (clinical and commercial), and Facility Design & Process Engineering. These services are delivered through the company's purpose-built Cell & Gene Therapy Centre in Bristol, UK—a 65,000 sq ft facility with 4 Grade C clean rooms, fill-finish capability, and 2x200L bioreactor scale. The integrated model enables seamless progression from early-phase strategy through to commercial readiness, with a 70% repeat business rate and 190+ clients served worldwide.

Product and service5 records
1Consulting Services
CategoryConsulting / Professional Services
Description

Expert CMC, regulatory and strategic consultancy for cell and gene therapy developers, covering CMC Consulting & Strategy, Cost of Goods analysis, Investor & Technical Due Diligence, GMP Compliance Consulting & QP Services, and Interim Leadership Positions to de-risk development and ensure regulatory success.

2Process Development
CategoryProcess Development / CDMO
Description

Optimisation and scale-up of CGT processes covering cell therapy, viral vector (AAV, lentivirus) and RNA technologies to enable seamless progression from preclinical development through to GMP manufacturing and commercialisation.

3Analytical Services
CategoryAnalytical / Quality Control Services
Description

Generation of high-quality analytical data to ensure product safety, efficacy and regulatory compliance across cell and gene therapy manufacturing, supporting QC release and stability testing.

4GMP Manufacturing
CategoryGMP Manufacturing / CDMO
Description

Regulatory-compliant, flexible GMP manufacturing services delivered from the MHRA MIA(IMP)-licensed Cell & Gene Therapy Centre, including Clinical Manufacturing, Commercial Manufacturing, Cell Banking, Fill Finish, and GMP Quality & Regulatory services for viral vectors, autologous and allogeneic cell therapies.

5Facility Design & Process Engineering
CategoryFacility Design / Engineering Consulting
Description

End-to-end facility planning services for cell and gene therapy manufacturers, from concept design through process engineering to operational execution; 45 facility designs completed to date for clients globally.

Scale indicator11 records

Each record includes

Type, Value, Description, Source

Partnership10 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-12-02
Description

Strategic collaboration between eXmoor Pharma and UCL's Translational Research Office (TRO) to accelerate development of cell and gene therapies from academic research into clinical application. The partnership provides UCL innovators earlier access to CMC expertise, process development, GMP manufacturing, and regulatory strategy support.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-11-26
Description

Strategic collaboration to develop a scalable pathway for cell and gene therapy manufacturing in the UK, integrating CVIC's early-phase clinical manufacturing expertise with eXmoor's later-phase clinical manufacturing capabilities. Focus on harmonizing technology transfer, quality systems, and regulatory expertise.

Strategic tierMinorTypeGTM or Marketing PartnerAnnounced on2025-09-24
Description

Co-hosted The CGT Success Blueprint event in Boston with Ori Biotech and Kincell Bio, bringing together CGT developers, CDMOs, and academic leaders to discuss manufacturing and strategy.

Strategic tierMinorTypeGTM or Marketing PartnerAnnounced on2025-09-24
Description

Co-hosted The CGT Success Blueprint event in Boston with Ori Biotech and Kincell Bio, featuring expert insights and patient perspective on CGT manufacturing.

5Siam Bioscience
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2025-09-23
Description

Strategic partnership to establish a center for cell and gene therapy development and manufacturing in Bangkok, Thailand. Provides comprehensive services including consultancy, process development, and GMP clinical and commercial manufacturing to support therapy developers in Thailand and Southeast Asia.

technologynetworks.com
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2025-09-02
Description

Collaboration to support developers of both autologous and allogeneic cell therapies. Combines Anthony Nolan's donor registry and expertise in cell collection with eXmoor's integrated process development and manufacturing services, emphasizing ethical sourcing and complete traceability of donor materials.

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2025-06-17
Description

Partnership to develop next-generation monocyte-based cell therapy for solid tumours, combining Signadori Bio's therapeutic approach with eXmoor's process development and manufacturing capabilities.

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2025-05-13
Description

Strategic partnership announced to accelerate cell and gene therapy innovation through new venture, combining KU Leuven's research capabilities with eXmoor's manufacturing expertise.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-09-24
Description

Multi-year manufacturing partnership for multiple autologous engineered CAR-Treg cell therapies for Phase 1/2 clinical studies. Builds on long-term relationship to provide dedicated GMP capacity at eXmoor's Cell & Gene Therapy Centre. Quell is the first manufacturing client in the new facility.

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2023-02-22
Description

Strategic process development partnership for Imophoron's ADDomer vaccine platform targeting RSV. eXmoor developing scalable manufacturing platform with future GMP manufacturing route at new facility.

Recent move9 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Global leader in CDMO services with significant cell and gene therapy capabilities including viral vector and cell therapy manufacturing. Offers a broad biologics portfolio and competes for the same CGT clients as eXmoor, but at much larger scale and global footprint.

TypeBroad incumbent
Description

Major CDMO with established cell therapy, viral vector, and biologics manufacturing services across multiple global sites. Provides comparable end-to-end development and manufacturing capabilities to eXmoor's clients, though at substantially larger scale and broader modality coverage.

TypeDirect peer
Description

UK-based specialist CDMO focused on lentiviral vector development and manufacturing for cell and gene therapies. Directly comparable to eXmoor's viral vector services, with eXmoor's CTO James Miskin previously serving as CTO at Oxford Biomedica.

TypeDirect peer
Description

Mid-to-large global CDMO offering cell and gene therapy, viral vector, and biologics manufacturing services. Direct competitor for CGT manufacturing contracts; eXmoor's CCO Manuel Balbuena previously held senior commercial roles at AGC Biologics.

TypeBroad incumbent
Description

Large contract research and manufacturing organization with significant cell and gene therapy CDMO capabilities following its acquisition of Cobra Biologics. Competes with eXmoor for viral vector and cell therapy manufacturing projects globally.

TypeDirect peer
Description

Specialist AAV and gene therapy CDMO operating a purpose-built GMP facility in Columbus, Ohio. Closely comparable to eXmoor's gene therapy vector manufacturing offering and competing for similar early-stage to clinical-stage gene therapy clients.

TypeBroad incumbent
Description

Diversified life sciences giant offering comprehensive CDMO services through its Patheon pharma services division including viral vector and cell therapy capabilities. Competes with eXmoor across multiple service categories at enterprise scale; eXmoor's CCO previously held roles in Thermo Fisher's Patheon unit.

TypeEmerging player
Description

Emerging cell therapy CDMO focused on autologous and allogeneic cell therapy manufacturing. Co-hosted CGT Success Blueprint event with eXmoor in Boston, indicating close community overlap; directly comparable in scale and target customer base.

TypeRegional player
Description

UK-based national innovation centre offering biologics and cell/gene therapy process development, scale-up, and GMP manufacturing services. Directly comparable to eXmoor's UK operations and consulting-plus-CDMO model; CEO Lucy Foley joined eXmoor from CPI.

TypeOthers
Description

UK-based innovation accelerator supporting cell and gene therapy development with process development and manufacturing facilities. Operates in adjacent rather than directly competitive space, but is closely connected to the same ecosystem of UK CGT developers that form eXmoor's customer base.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers10 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles9 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

eXmoor Pharma

Cell and Gene Therapy CDMO Servicesexmoorpharma.com

eXmoor Pharma is an integrated UK-based cell and gene therapy CDMO offering CMC consulting, process development, analytical services, GMP manufacturing, and facility design. Founded in 2004, it serves 190+ biotech, academic, and pharma clients from its MHRA-licensed 65,000 sq ft Bristol facility with 80+ experts.

What eXmoor Pharma does

eXmoor Pharma is a UK-based integrated cell and gene therapy (CGT) contract development and manufacturing organization (CDMO) headquartered in Bristol. Founded in 2004 and operating in the CGT sector since 2007, the company delivers five interconnected service pillars: CMC consulting, process development, analytical services, GMP manufacturing, and facility design. Its purpose-built Cell & Gene Therapy Centre comprises 65,000 sq ft with four independent Grade C GMP clean rooms, a dedicated fill-finish suite, and capacity for 2x200L bioreactor scale or five autologous cell therapy stations. The facility received MHRA MIA(IMP) licensing in August 2024, enabling full GMP-grade manufacture for clinical trials.

The company serves 190+ clients globally including biotech companies (Quell Therapeutics, Tenpoint, Tavira, Imophoron), academic institutions (King's College London, UCL), nonprofits (Cancer Research UK, Anthony Nolan), and NHS partners (Royal Free London). Its differentiated integrated model embeds 20+ years of consultancy expertise across the full CMC journey, from early-phase strategy through to commercial readiness. The company employs 80+ experts, with 70% repeat business rate, and is backed by Kineticos Ventures and MVM Partners following a $35M Series A in May 2023.

Revenue is generated primarily through professional services fees for consulting, process development, and analytical work, plus managed services revenue from GMP manufacturing. The company targets enterprise clients through a direct sales team led by a Chief Commercial Officer, supplemented by industry events (BIO, ISCT, ESGCT), academic clinics with partner universities, and strategic regional partnerships including a Bangkok-based Southeast Asia expansion with Siam Bioscience announced in 2025. Geographic reach extends across the UK, US, Europe, and Southeast Asia, with planned facility expansion of 12,000 sq ft and headcount growth to 200 by 2027.

eXmoor Pharma firmographics

Firmographics
Name
eXmoor Pharma
Legal name
eXmoor pharma concepts ltd
Website
https://exmoorpharma.com
Company type
Private
Founded year
2004
Operating status
Operating
Headcount range
51–100 employees
Short description
eXmoor Pharma is an integrated UK-based cell and gene therapy CDMO offering CMC consulting, process development, analytical services, GMP manufacturing, and facility design. Founded in 2004, it serves 190+ biotech, academic, and pharma clients from its MHRA-licensed 65,000 sq ft Bristol facility with 80+ experts.
Ownership category
akta.pro rank

eXmoor Pharma industry classification

Industry
Product category
Cell and Gene Therapy CDMO Services
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417), Pharmaceutical and Medicine Manufacturing (32541)
SIC
Services-Commercial Physical & Biological Research (8731), Services-Medical Laboratories (8071)
akta.pro industry
PRIMARYHLAAACAJ
Gene Therapy Vector Manufacturing & CDMO Services
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAGABAG
Drug Substance–Drug Product Integrated CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAK
Clinical Trial Material (CTM) Manufacturing & Supply CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGAHAL
GMP Scale-Up, Tech Transfer & Process Validation (PPQ)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services

Keywords

  • Cell and gene therapy CDMO
  • GMP manufacturing services
  • Biopharmaceutical consulting
  • Process development services
  • Facility design engineering

Where eXmoor Pharma is headquartered

Location

Headquarters

HQ city
Bristol
HQ country
United Kingdom
HQ region
Europe

Offices3 records

Markets served

eXmoor Pharma business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Infrastructure, Technology or R&D, Marketing or Sales, Supply Chain

Revenue model

  1. Consulting Services: CMC consulting, regulatory strategy, cost of goods analysis, investor and technical due diligence, GMP compliance consulting, and interim leadership positions. Revenue generated through project-based consulting engagements.
  2. Process Development Services: Process development for cell therapy, viral vectors, and RNA technologies including optimization and scale-up services.
  3. Analytical Services: Quality control and analytical testing services to ensure product safety, efficacy, and regulatory compliance.
  4. GMP Manufacturing: Clinical and commercial manufacturing services including clinical manufacturing, commercial manufacturing, cell banking, and fill finish under MHRA-licensed facility.
  5. Facility Design & Process Engineering: Concept design and process engineering services for CGT facility planning.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractCustom project-based pricing for consulting and development services

Go-to-market motion2 records

Distribution channels4 records

Marketing channels8 records

eXmoor Pharma product offering

Product offering

Core offering

eXmoor Pharma is an integrated cell and gene therapy Contract Development and Manufacturing Organization (CDMO) that combines 20+ years of CMC and regulatory consultancy with a purpose-built 65,000 sq ft MHRA-licensed GMP manufacturing facility in Bristol, UK. It delivers end-to-end services across consulting, process development, analytical services, GMP manufacturing (clinical and commercial), and facility design for viral vectors, autologous and allogeneic cell therapies, and RNA technologies. The integrated model enables clients to progress therapies from early-phase strategy through to commercial readiness under a single provider.

Product overview

eXmoor Pharma is an integrated cell and gene therapy CDMO offering five interconnected service pillars: Consulting Services (CMC strategy, GMP compliance, QP services, due diligence), Process Development (cell therapy, viral vector, RNA), Analytical Services, GMP Manufacturing (clinical and commercial), and Facility Design & Process Engineering. These services are delivered through the company's purpose-built Cell & Gene Therapy Centre in Bristol, UK—a 65,000 sq ft facility with 4 Grade C clean rooms, fill-finish capability, and 2x200L bioreactor scale. The integrated model enables seamless progression from early-phase strategy through to commercial readiness, with a 70% repeat business rate and 190+ clients served worldwide.

Differentiator

Problem solved

Functional benefit

Products and services

  • Consulting Services Expert CMC, regulatory and strategic consultancy for cell and gene therapy developers, covering CMC Consulting & Strategy, Cost of Goods analysis, Investor & Technical Due Diligence, GMP Compliance Consulting & QP Services, and Interim Leadership Positions to de-risk development and ensure regulatory success.
  • Process Development Optimisation and scale-up of CGT processes covering cell therapy, viral vector (AAV, lentivirus) and RNA technologies to enable seamless progression from preclinical development through to GMP manufacturing and commercialisation.
  • Analytical Services Generation of high-quality analytical data to ensure product safety, efficacy and regulatory compliance across cell and gene therapy manufacturing, supporting QC release and stability testing.
  • GMP Manufacturing Regulatory-compliant, flexible GMP manufacturing services delivered from the MHRA MIA(IMP)-licensed Cell & Gene Therapy Centre, including Clinical Manufacturing, Commercial Manufacturing, Cell Banking, Fill Finish, and GMP Quality & Regulatory services for viral vectors, autologous and allogeneic cell therapies.
  • Facility Design & Process Engineering End-to-end facility planning services for cell and gene therapy manufacturers, from concept design through process engineering to operational execution; 45 facility designs completed to date for clients globally.

Quantifiable outcome

  • 70% repeat business rate demonstrating high client satisfaction
  • +4 more outcomes

Companies that use eXmoor Pharma

Customer profile

Named customers10 records

Segments4 records

Ideal customer profiles4 records

eXmoor Pharma technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature6 records

eXmoor Pharma partnerships and signals

Strategic signal

Partnerships

Ten partnerships are on record, tiered core, minor and major.

  • University College London (UCL)coreStrategic or Co-development Partner · 2 December 2025Strategic collaboration between eXmoor Pharma and UCL's Translational Research Office (TRO) to accelerate development of cell and gene therapies from academic research into clinical application. The partnership provides UCL innovators earlier access to CMC expertise, process development, GMP manufacturing, and regulatory strategy support.
  • Royal Free London NHS Foundation TrustcoreStrategic or Co-development Partner · 26 November 2025Strategic collaboration to develop a scalable pathway for cell and gene therapy manufacturing in the UK, integrating CVIC's early-phase clinical manufacturing expertise with eXmoor's later-phase clinical manufacturing capabilities. Focus on harmonizing technology transfer, quality systems, and regulatory expertise.
  • Ori BiotechminorGTM or Marketing Partner · 24 September 2025Co-hosted The CGT Success Blueprint event in Boston with Ori Biotech and Kincell Bio, bringing together CGT developers, CDMOs, and academic leaders to discuss manufacturing and strategy.
  • Kincell BiominorGTM or Marketing Partner · 24 September 2025Co-hosted The CGT Success Blueprint event in Boston with Ori Biotech and Kincell Bio, featuring expert insights and patient perspective on CGT manufacturing.
  • Siam BiosciencemajorStrategic or Co-development Partner · 23 September 2025Strategic partnership to establish a center for cell and gene therapy development and manufacturing in Bangkok, Thailand. Provides comprehensive services including consultancy, process development, and GMP clinical and commercial manufacturing to support therapy developers in Thailand and Southeast Asia.
  • Anthony Nolan Cell Therapy and Laboratory ServicesmajorStrategic or Co-development Partner · 2 September 2025Collaboration to support developers of both autologous and allogeneic cell therapies. Combines Anthony Nolan's donor registry and expertise in cell collection with eXmoor's integrated process development and manufacturing services, emphasizing ethical sourcing and complete traceability of donor materials.
  • Signadori BiomajorStrategic or Co-development Partner · 17 June 2025Partnership to develop next-generation monocyte-based cell therapy for solid tumours, combining Signadori Bio's therapeutic approach with eXmoor's process development and manufacturing capabilities.
  • KU LeuvenmajorStrategic or Co-development Partner · 13 May 2025Strategic partnership announced to accelerate cell and gene therapy innovation through new venture, combining KU Leuven's research capabilities with eXmoor's manufacturing expertise.
  • Quell TherapeuticscoreStrategic or Co-development Partner · 24 September 2024Multi-year manufacturing partnership for multiple autologous engineered CAR-Treg cell therapies for Phase 1/2 clinical studies. Builds on long-term relationship to provide dedicated GMP capacity at eXmoor's Cell & Gene Therapy Centre. Quell is the first manufacturing client in the new facility.
  • ImophoronmajorStrategic or Co-development Partner · 22 February 2023Strategic process development partnership for Imophoron's ADDomer vaccine platform targeting RSV. eXmoor developing scalable manufacturing platform with future GMP manufacturing route at new facility.

Scale indicators11 records

Recent moves9 records

Expansion highlights5 records

eXmoor Pharma competitors and assessment

Company assessment

Broad incumbents

  • Lonza Group: Global leader in CDMO services with significant cell and gene therapy capabilities including viral vector and cell therapy manufacturing. Offers a broad biologics portfolio and competes for the same CGT clients as eXmoor, but at much larger scale and global footprint.
  • Catalent: Major CDMO with established cell therapy, viral vector, and biologics manufacturing services across multiple global sites. Provides comparable end-to-end development and manufacturing capabilities to eXmoor's clients, though at substantially larger scale and broader modality coverage.
  • Charles River Laboratories: Large contract research and manufacturing organization with significant cell and gene therapy CDMO capabilities following its acquisition of Cobra Biologics. Competes with eXmoor for viral vector and cell therapy manufacturing projects globally.
  • Thermo Fisher Scientific (Patheon): Diversified life sciences giant offering comprehensive CDMO services through its Patheon pharma services division including viral vector and cell therapy capabilities. Competes with eXmoor across multiple service categories at enterprise scale; eXmoor's CCO previously held roles in Thermo Fisher's Patheon unit.

Direct peers

  • Oxford Biomedica: UK-based specialist CDMO focused on lentiviral vector development and manufacturing for cell and gene therapies. Directly comparable to eXmoor's viral vector services, with eXmoor's CTO James Miskin previously serving as CTO at Oxford Biomedica.
  • AGC Biologics: Mid-to-large global CDMO offering cell and gene therapy, viral vector, and biologics manufacturing services. Direct competitor for CGT manufacturing contracts; eXmoor's CCO Manuel Balbuena previously held senior commercial roles at AGC Biologics.
  • Andelyn Biosciences: Specialist AAV and gene therapy CDMO operating a purpose-built GMP facility in Columbus, Ohio. Closely comparable to eXmoor's gene therapy vector manufacturing offering and competing for similar early-stage to clinical-stage gene therapy clients.

Emerging players

  • Kincell Bio: Emerging cell therapy CDMO focused on autologous and allogeneic cell therapy manufacturing. Co-hosted CGT Success Blueprint event with eXmoor in Boston, indicating close community overlap; directly comparable in scale and target customer base.

Regional players

  • Centre for Process Innovation (CPI): UK-based national innovation centre offering biologics and cell/gene therapy process development, scale-up, and GMP manufacturing services. Directly comparable to eXmoor's UK operations and consulting-plus-CDMO model; CEO Lucy Foley joined eXmoor from CPI.

Others

  • Cell and Gene Therapy Catapult: UK-based innovation accelerator supporting cell and gene therapy development with process development and manufacturing facilities. Operates in adjacent rather than directly competitive space, but is closely connected to the same ecosystem of UK CGT developers that form eXmoor's customer base.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

eXmoor Pharma social profiles

Digital presence

eXmoor Pharma compliance and trust

Trust signal

Compliance1 record

eXmoor Pharma financial estimates

Financial estimate

Revenue estimate

Valuation estimate

eXmoor Pharma leadership team

Management profile

Number of profiles

Profiles9 records

eXmoor Pharma funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

eXmoor Pharma M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about eXmoor Pharma

What does eXmoor Pharma do?

eXmoor Pharma is an integrated cell and gene therapy Contract Development and Manufacturing Organization (CDMO) that combines 20+ years of CMC and regulatory consultancy with a purpose-built 65,000 sq ft MHRA-licensed GMP manufacturing facility in Bristol, UK. It delivers end-to-end services across consulting, process development, analytical services, GMP manufacturing (clinical and commercial), and facility design for viral vectors, autologous and allogeneic cell therapies, and RNA technologies. The integrated model enables clients to progress therapies from early-phase strategy through to commercial readiness under a single provider.

Is eXmoor Pharma a public or private company?

eXmoor Pharma is a private company. It is classified as venture growth investor backed and is currently operating.

When was eXmoor Pharma founded?

eXmoor Pharma was founded in 2004. It employs 51 to 100 people.

Where is eXmoor Pharma based?

eXmoor Pharma is headquartered in Bristol, United Kingdom, in the Europe region.

How does eXmoor Pharma make money?

Five revenue lines are on record. Consulting Services are the primary driver. The others are process Development Services, analytical Services, GMP Manufacturing and facility Design & Process Engineering.

Who are eXmoor Pharma's main competitors?

Broad incumbents on record are Lonza Group, Catalent, Charles River Laboratories and Thermo Fisher Scientific (Patheon). Direct peers are Oxford Biomedica, AGC Biologics and Andelyn Biosciences. Kincell Bio is listed as an emerging player. Centre for Process Innovation (CPI) is listed as a regional player. Cell and Gene Therapy Catapult is listed as an others.

Does eXmoor Pharma have an API?

No public API is recorded for eXmoor Pharma.

What industry is eXmoor Pharma in?

eXmoor Pharma's product category is Cell and Gene Therapy CDMO Services. Its primary akta.pro industry code is HLAAACAJ, Gene Therapy Vector Manufacturing & CDMO Services, with a secondary code of HLAGABAG, Drug Substance–Drug Product Integrated CDMO. Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Silicon RepublicFrom a pharmacy job at 13 to leading a cell and gene therapy firmLucy Foley, CEO of Exmoor Pharma, traces her career from a pharmacy job at 13 to leading a cell and gene therapy firm. She previously led the UK's RNA Centre of Excellence during the pandemic and now focuses on scaling therapies for thousands of patients. She highlights AI and automation as underused resources for manufacturing and emphasizes the need for lower-cost, higher-volume production.Lab ManagerShimadzu Acquires Plasmion GmbH to Bring SICRIT Ion Source Technology to Next-Generation Mass SpectrometersThis article features an interview with three women leaders in life sciences — Lucy Foley (CEO of eXmoor Pharma), Claudia Zylberberg (co-founder of Akron Bio), and Jackie Kunzler (SVP and global head of R&D for Terumo BCT) — conducted for International Women’s Day, exploring their career challenges, perspectives on gender bias, and advice for the next generation. The leaders discuss overcoming credibility barriers, balancing ambition with family responsibilities, and challenging outdated expectations about what scientists should look or behave like. They emphasize resilience, authentic leadership, and the importance of creating supportive, flexible work environments to retain women in STEM fields.PharmaTimeseXmoor Pharma and UCL establish strategic cell and gene therapy collaborationeXmoor Pharma has established a strategic collaboration with the Translational Research Office and University College London to accelerate the development of cell and gene therapies. The partnership will facilitate UCL innovators' access to eXmoor's expertise and services, enhancing the transition from academic research to clinical application. It aims to streamline the development process and overcome technical and regulatory challenges in CGT candidates.BioProcess InternationalEthical sourcing and manufacturing in cell therapyIn September, contract development and manufacturing organization eXmoor Pharma and cell-therapy service charity Anthony Nolan Cell Therapy and Laboratory Services entered a collaboration to support developers of both autologous and allogeneic cell therapies. The partnership combines Anthony Nolan's donor registry and expertise in cell collection with eXmoor's integrated process development and manufacturing services, emphasizing ethical sourcing and complete traceability of donor materials from collection to patient release. Industry experts note that while autologous treatments currently lead in commercialization and efficacy, allogeneic approaches show promising developments expected to yield clinical results in the coming years.GenengnewseXmoor Pharma and UCL Collaborate to Accelerate the Advancement of Cell and Gene TherapiesCDMO eXmoor Pharma and the Translational Research Office at University College London formed a strategic collaboration to accelerate the development of cell and gene therapies from academic research into clinical application. The partnership combines UCL's translational research expertise with eXmoor's GMP manufacturing and consultancy capabilities to reduce risk, cost, and complexity of technology development. Both organizations aim to bridge the gap between academic innovation and clinical readiness through shared access to CMC consulting, regulatory strategy, laboratory capacity, and GMP manufacturing for early clinical studies.UCLUCL and eXmoor Pharma forge a strategic collaboration to advance cell and gene therapiesUCL's Translational Research Office and eXmoor Pharma have formed a strategic collaboration to accelerate the development of cell and gene therapies from academic research into clinical application. The partnership will give UCL innovators earlier access to CMC expertise, process development, GMP manufacturing, and regulatory strategy support. eXmoor Pharma, described as the UK's only fully integrated cell and gene therapy CDMO, will benefit from direct collaboration with UCL's translational researchers to stay at the forefront of evolving CGT modalities.PharmaTimeseXmoor Pharma and Royal Free London link to strengthen UK gene therapyeXmoor Pharma and Royal Free London NHS Foundation Trust announced a strategic partnership on 26 November to enhance cell and gene therapy development and manufacturing in the UK. The collaboration aims to streamline processes, accelerate timelines, and position the UK as a leader in advanced therapeutics.PharmiWeb.comeXmoor Pharma and Royal Free London launch strategic collaboration to strengthen UK cell and gene therapy manufacturing pathwayeXmoor Pharma and Royal Free London NHS Foundation Trust's Cell and Vector Innovation Centre (CVIC) have announced a strategic collaboration to create a seamless pathway for cell and gene therapy development and manufacturing in the UK. The partnership combines CVIC's early-phase clinical manufacturing expertise with eXmoor's later-phase capabilities and planned commercial manufacturing license, aiming to reduce complexity, accelerate timelines, and strengthen the UK's position as a global leader in advanced therapeutics. The collaboration will focus on harmonizing technology transfer protocols, quality systems, regulatory strategy, and staff training across both organisations.ContractpharmaeXmoor Pharma, Royal Free London Join Forces to Strengthen UK CGT Manufacturing PathwayeXmoor Pharma and Royal Free London NHS Foundation Trust have formed a strategic collaboration to enhance the cell and gene therapy development and manufacturing pathway in the UK. This partnership aims to combine their respective manufacturing capabilities to streamline the transition from early-phase clinical trials to commercial production. Ultimately, the collaboration seeks to bolster the UK’s position as a leader in advanced therapeutics by creating clearer pathways for innovators to navigate the manufacturing process.